Gain-of-function mutations in the tumor suppressor gene p53

Clinical Cancer Research

Volumn 6, Issue 6, 2000, Pages 2138-2145

  Van Oijen, Monique G C T ^a   Slootweg, Pieter J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53; TRANSCRIPTION FACTOR;

CARCINOGENESIS; CELL CYCLE; CELL SURVIVAL; DOMINANT GENE; GENE EXPRESSION; GENE LOSS; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

ALLELES; ANIMALS; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; MICE; MODELS, GENETIC; MUTATION; PROTEIN STRUCTURE, SECONDARY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034122591     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Huang, P. S., and Heimbrook, D. C. Oncogene products as therapeutic targets for cancer. Curr. Opin. Oncol., 9: 94-100, 1997.
2. Hainaut, P., and Hollstein, M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res., 77: 81-137, 2000.
3. Béroud, C., and Soussi, T. p53 gene mutation: software and database. Nucleic Acids Res., 26: 200-204, 1998.
4. Hollstein, M., Moeckel, G., Hergenhahn, M., Spiegelhalder, B., Keil, M., Werle-Schneider, G., Bartsch, H., and Brickman, J. On the origins of tumor mutations in cancer genes: insights from the p53 gene. Mutat. Res., 405: 145-154, 1998.
5. Kropveld, A., Rozemuller, E. H., Leppers, F. G. J., Scheidel, K. C., de Weger, R. A., Koole, R., Hordijk, G. J., Slootweg, P. J., and Tilanus, M. G. J. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of the head and neck squamous cell cancers. Lab. Invest., 79: 347-353, 1999.
6. Preudhomme, C., and Fenaux, P. The clinical significance of mutations of the p53 tumor suppressor gene in haematological malignancies. Br. J. Haematol., 98: 502-511, 1997.
7. Prives, C., and Hall, P. A. The p53 pathway. J. Pathol., 187: 112-126, 1999.
8. El-Deiry, W. Regulation of p53 downstream genes. Semin. Cancer Biol., 8: 345-357, 1998.
9. May, P., and May, E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene, 18: 7621-7636, 1999.
10. Ashcroft, M., and Vousden, K. H. Regulation of p53 stability. Oncogene, 18: 7637-7643, 1999.
11. Walker, D. R., Bond, J. P., Tarone, R. E., Harris, C. C., Makalowski, W., Boguski, M. S., and Greenblatt, M. S. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene. 19: 211-218, 1999.
12. Cho, Y., Gorina, S., Jeffrey, P. D., and Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (Washington DC). 265: 346-355, 1994.
13. Kirsch, D. G., and Kastan, M. B. Tumor suppressor p53: implications for tumor development and prognosis. J. Clin. Oncol., 16: 3158-3168, 1998.
14. Sjogren, S., Inganas, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L., and Bergh, J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst., 88: 173-182, 1996.
15. Chen, Y., Chen, P-L., and Lee, W-H. Hot-spot mutants interact specifically with two cellular proteins during progression on cell cycle. Mol. Cell. Biol., 14: 6764-6772, 1994.
16. Müller, B., Paulsen, D., and Deppert, W. Specific binding of MAR/SAR DNA-elements by mutant p53. Oncogene. 12: 1941-1952, 1996.
17. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., and Levine, A. J. Gain of function mutations in p53. Nat. Genet., 4: 42-45, 1993.
18. Kawamura, M., Yamashita, T., Segawa, K., Kaneuchi, M., Shindoh, M., and Fujinaga. K. The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity. Oncogene, 12: 2361-2367, 1996.
19. Gualberto, A., Aldape, K., Kozakiewicz, K., and Tlsty, T. D. An oncogenic form of p53 confers a dominant, gain of function phenotype that disrupts spindle checkpoint control. Proc. Natl. Acad. Sci. USA, 95: 5166-5171, 1998.
20. 172H mutant and p53-knockout mice after chemical carcinogenesis: evidence for a gain of function. Mol. Carcinog., 23: 185-192, 1998.
21. Agapova, L. S., Ilyinskaya, G. V., Turovets, N. A., Ivanov, A. V., Chumakov, P. M., and Kopnin, B. P. Chromosome changes caused by alterations of p53 expression. Mutat. Res., 354: 129-138, 1996.
22. Li, R., Sutphin, P. D., Schwartz, D., Matas, D., Almog, N., Wolkowicz, R., Goldfinger, N., Pei, H., Prokocimer, M., and Rotter, V. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene, 16: 3269-3277, 1998.
23. Lassus, P., Bertrand, C., Zugasti, O., Chambon, J-P., Soussi, T., Mathieu-Mahul, D., and Hibner, U. Anti-apoptotic activity of p53 maps to the COOH-terminal domain and is retained in a highly oncogenic natural mutant. Oncogene, 18: 4699-4709, 1999.
24. Gloushankova, N., Ossovskaya, V., Vasiliev, J., Chumakov, P., and Kopnin, B. Changes in p53 expression can modify cell shape of ras-transformed fibroblasts and epitheliocytes. Oncogene, 15: 2985-2989, 1997.
25. Blandino, G., Levine, A. J., and Oren, M. Mutant p53 gain of function: differential effects p53 mutants on resistance of cultured cells to chemotherapy. Oncogene, 18: 477-485, 1999.
26. Cardinali, M., Kratochvil, F. J., Ensley, J. F., Robbins, K. C., and Yeudall, W. A. Functional characterization in vivo of mutant p53 molecules derived from squamous cell carcinomas of the head and neck. Mol. Carcinog., 18: 78-88, 1997.
27. Lanyi, A., Deb, D., Seymour, R. C., Ludes-Meyers, J. H., Subler, M. A., and Deb, S. "Gain of function" phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nuclei acid-binding domain. Oncogene, 16: 3169-3176, 1998.
28. Shaulsky, G., Goldfinger, N., and Rotter, V. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res., 51: 5232-5237, 1991.
29. Hsiao, M., Low, J., Dorn, E., Ku, D., Pattengale, P., Yeargin, J., and Haas, M. Gain-of-function mutations of the p53 gene induce lymphohaematopoietic metastatic potential and tissue invasiveness. Am. J. Pathol., 145: 702-714, 1994.
30. Brachmann, R. K., Vidal, M., and Boeke, J. D. Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc. Natl. Acad. Sci. USA, 93: 4091-4095, 1996.
31. Varley, J. M., Thorncroft, M., McGown, G., Appleby, J., Kelsey, A. M., Tricker, K. J., Evans, D. G. R., and Birch, J. M. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. Oncogene, 14: 865-871, 1997.
32. Erber, R., Conradt, C., Homann, N., Enders, C., Finck, M., Dietz, A., Weidauer, H., and Bosch, F. X. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene, 16: 1671-1679, 1998.
33. McLure, K. G., and Lee, P. W. How p53 binds DNA as a tetramer. EMBO J., 17: 3342-3350, 1998.
34. McLure, K. G., and Lee, P. W. P53 DNA binding can be modulated by factors that alter the conformational equilibrium. EMBO J., 18: 763-770, 1999.
35. Frebourg, T., Sadelein, M., Ng, Y-S., Kassel, J., and Friend, S. H. Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. Cancer Res., 54: 878-881, 1994.
36. Birch, J. M., Blair, V., Kelsey, A. M., Evans, D. G., Harris, M., Tricker, K. J., and Varley, J. M. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene, 17: 1061-1068, 1998.
37. Millner, J., and Medcalf, E. A. Cotranslation of activated mutant p53 with wild type drives the wild type p53 protein into the mutant conformation. Cell, 65: 765-774, 1991.
38. Deb, S., Jackson, C. T., Subler, M. A., and Martin, D. W. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J. Virol., 66: 6164-6170, 1992.
39. Frazier, M. W., He, X., Wang, J., Gu, Z., Cleveland, J. L., and Zambetti, G. P. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete c-terminal domain. Mol. Cell. Biol., 18: 3735-3743, 1998.
40. Ludes-Meyers, J. H., Subler, M. A., Shivakumar, C. V., Munoz, R. M., Jiang, P., Bigger, J. E., Brown, D. R., Deb, S. P., and Deb, S. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol. Cell. Biol., 16: 6009-6019, 1996.
41. Gorgoulis, V. G., Zacharatos, P. V., Manolis, E., Ikonomopoulos, J. A., Damalas, A., Lamprinopoulos, C., Rassidakis, G. Z., Zoumpourlis, V., Kotsinas, A., Rassidakis, A. N., Halazonetis, T. D., and Kittas, C. Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene. Br. J. Cancer, 77: 374-384, 1998.
42. Kieser, A., Weich, H. A., Brandner, G., Marme, D., and Kolch, W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene, 9: 963-969, 1994.
43. Werner, H., Karnieli, E., Rauscher, F. J., and LeRoith, D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl. Acad. Sci. USA, 93: 8318-8323, 1996.
44. Margulies, L., and Sehgal, P. B. Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBP β (NF-IL6) activity by p53 species. J. Biol. Chem., 268: 15096-15100, 1993.
45. Ueba, T., Nosaka, T., Takahashi, J. A., Shibata, F., Florkiewicz, R. Z., Vogelstein, B., Oda, Y., Kikuchi, H., and Hatanaka, M. Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc. Natl. Acad. Sci. USA, 91: 9009-9013, 1994.
46. Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 13: 9-22, 1999.
47. Sigalas, I., Calvert, A. H., Anderson, J. J., Neal, D. E., and Lunec, J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat. Med., 2: 912-917, 1996.
48. Stein, W. D. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol. Rev., 77: 545-590, 1997.
49. Vasey, P. A., Jones, N. A., Jenkins, S., Dive, C., and Brown, R. Cisplatin, camptothecin, and Taxol sensitivities of cells with p53-associated multidrug resistance. Mol. Pharmacol., 50: 1536-1540, 1996.
50. Weller, M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res., 292: 435-445, 1998.
51. Peller, S. Clinical implication of p53: effect on prognosis, tumor progression and chemotherapy response. Semin. Cancer Biol., 8: 379-387, 1998.
52. Iwamoto, K. S., Mizuno, T., Ito, T., Tsuyama, N., Kyoizumi, S., and Seyama, T. Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival. Cancer Res., 56: 3862-3865, 1996.
53. Iwamoto, K. S., Mizuno, T., Seyama, T., and Kyoizumi, S. Mutant p53: epigenetic mutator of the T-cell receptor via induction of methylation. Mol. Carcinog., 25: 113-121, 1999.
54. 135. Oncogene, 8: 3417-3419, 1993.
55. Flaman, J-M., Robert, V., Lenglet, S., Moreau, V., Iggo, R., and Frebourg, T. Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast. Oncogene, 16: 1369-1372, 1998.
56. Kaelin, W. G. The p53 gene family. Oncogene, 18: 7701-7705, 1999.
57. ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J., 18: 22-27, 1999.
58. Zhou, M., Yeager, A. M., Smith, S. D., and Findley, H. W. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood, 85: 1608-1614, 1995.
59. Garkavtsev, I., Grigorian, I. A., Ossovskaya, V. S., Chernov, M. V., Chumakov, P. M., and Gudkov, A. V. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature (Lond.), 391: 295-298, 1998.
60. Lin, J., Teresky, A. K., and Levine, A. J. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene, 10: 2387-2390, 1995.
61. Chène, P., and Bechter, E. P53 mutants without a functional tetramerisation domain are not oncogenic. J. Mol. Biol., 286: 1269-1274, 1999.
62. Gallagher, W. M., Argentini, M., Sierra, V., Bracco, L., Debussche, L., and Conseiller, E. MBP1: a novel mutant p53-specific protein partner with oncogenic properties. Oncogene, 18: 3608-3616, 1999.
63. Bode, J., Schlake, T., Rios-Ramirez, M., Mielke, C., Stengert, M., Kay, V., and Klehr-Wirth, D. Scaffold/matrix-attached regions: structural properties creating transcriptionally active loci. Int. Rev. Cytol., 162A: 389-454, 1995.
64. Albor, A., Kaku, S., and Kulesz-Martin, M. Wild-type and mutant forms of p53 activate human topoisomerase I: a possible mechanism for gain of function in mutants. Cancer Res., 58: 2091-2094, 1998.
65. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem., 65: 635-692, 1996.
66. Bullock, P., Champoux, J. J., and Botchman, M. Association of cross-over points with topoisomerase I cleavage sites: a model for non-homologous recombination. Science (Washington DC), 230: 954-958, 1985.
67. Tomizawa, Y., Kohno, T., Fujita, T., Kiyama, M., Saito, R., Noguchi, M., Matsuno, Y., Hirohashi, S., Yamaguchi, N., Nakajima, T., and Yokota, J. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene, 18: 1007-1014, 1999.
68. Hashimoto, T., Tokuchi, Y., Hayashi, M., Kobayashi, Y., Nishida, K., Hayashi, S., Ishikawa, Y., Tsuchiya, S., Nakagawa, K., Hayashi, J., and Tsuchiya, E. p53 null mutations undetected by immunohistochemical staining predict poor outcome with early-stage non-small cell lung carcinomas. Cancer Res., 59: 5572-5577, 1999.
69. Huang, C., Taki, T., Adachi, M., Konishi, T., Higashiyama, M., and Miyake, M. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. Oncogene, 16: 2469-2477, 1999.
70. Borresen, A. L., Andersen, T. I., Eyfjord, J. E., Cornelis, R. S., Thoracius, S., Borg, A., Johansson, U., Theillet, C., Scherneck, S., and Hartman, S. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer, 14: 71-75, 1995.
71. Aas, T., Borresen, A. L., Geisler, S., Smith-Sorensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., and Lonning, P. E. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med., 2: 811-814, 1996.
72. Berns, E. M., van Staveren, I. L., Look, M. P., Smid, M., Klijn, J. G., and Foekens, J. A. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br. J. Cancer, 77: 1130-1136, 1999.
73. Bergh, J., Norberg, T., Sjogren, S., Lindgren, A., and Holmberg, L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med., 1: 1029-1034, 1995.
74. Smith, P. D., Crossland, S., Parker, G., Osin, P., Brooks, L., Waller, J., Pilip, E., Crompton, M. R., Gusterson, B. A., Allday, M. J., and Crook, T. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. Oncogene, 18: 2451-2459, 1999.
75. Jervall, P., Maniken, M., Kattunen, T., Makela, J., and Vihko, P. Conserved region mutations of the p53 gene are concentrated in distal colorectal cancers. Int. J. Cancer, 74: 97-101, 1997.
76. Borresen-Dale, A. L., Lothe, R. A., Meling, G. I., Hainaut, P., Rognum, T. O., and Skovlund, E. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin. Cancer Res., 4: 203-210, 1998.
77. Wen, W. H., Reles, A., Runnebaum, I. B., Sullivan-Halley, J., Bernstein, L., Jones, L. A., Felix, J. C., Kreienberg, R., El-Naggar, A., and Press, M.F. P53 mutations and expression in ovarian cancers: correlation with overall survival. Int. J. Gynecol. Pathol., 18: 29-41, 1999.
78. Sood, A. K., Sorosky, J. I., Dolan, M., Anderson, B., and Buller, R. E. Distant metastases in ovarian cancer: association with p53 mutations. Clin. Cancer Res., 5: 2485-2490, 1999.
79. Nielsen, L. L., and Maneval, D. C. p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther., 5: 52-63, 1998.
80. Clayman, G. L., El-Naggar, A. K., McDonnell, T. J., Zhang, W. W., Goepfert, H., Taylor, D. L., and Liu, T. J. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous cell carcinoma. Cancer Res., 55: 1-6, 1995.
81. Roth, J. A., Nguyen, D., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Ferson, D. Z., Hong, W. K., Komaki, R., Lee, J. J., Nesbitt, J. C., Pisters, K. M., Putnam, J. B., Schea, R., Shin, D. M., Walsh, G. L., Dolormente, M. M., Han, C. I., Martin, F. D., Yen, N., Xu, K., Stephens, L. C., McDonnell, T. J., Mukhopadhyay, T., and Cai, D. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med., 2: 985-991, 1996.
82. Pirollo, K. F., Hao, Z., Rait, A., Jang, Y. J., Fee, W. E., Jr., Ryan, P., Chiang, Y., and Chang, E. H. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene, 14: 1735-1746, 1997.
83. Ho, P. T. C., and Parkinson, D. R. Antisense oligonucleotides as therapeutics for malignant diseases. Semin. Oncol., 24: 187-202, 1997.
84. Skilling, J. S., Squatrito, R. C., Connor, J. P., Niemann, T., and Buller, R. E. p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines. Gynecol. Oncol., 60: 72-80, 1996.
85. Wieczorek, A. M., Waterman, J. L., Waterman, M. J., and Halazonetis, T. D. Structure-based rescue of common tumor-derived p53 mutants. Nat. Med., 2: 1143-1146, 1996.
86. Selivanova, G., Ryabchenko, L., Jansson, E., Iotsova, V., and Wiman, K. G. Reactivation of mutant p53 through interaction of a c-terminal peptide with the core domain. Mol. Cell. Biol., 19: 3395-3402, 1999.
87. Foster, B. A., Coffey, H. A., Morin, M. J., and Rastinejad, F. Pharmacological rescue of mutant p53 conformation and function. Science (Washington DC), 286: 2507-2510, 1999.
88. Caron de Fromentel, C., Gruel, N., Venot, C., Debussche, L., Conseiller, E., Dureuil, C., Teillaud, J. L., Tocque, B., and Bracco. L. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene, 18: 551-557, 1999.